


PRODUCT INFORMATION



SB 222200

Item No. 29422

CAS Registry No.: 174635-69-9
Formal Name: 3-methyl-2-phenyl-N-
[(1S)-1-phenylpropyl]-4-
quinolinecarboxamide
MF: C₂₆H₂₄N₂O
FW: 380.5
Purity: ≥95%
UV/Vis.: λ_{max}: 232 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SB 222200 is supplied as a crystalline solid. A stock solution may be made by dissolving the SB 222200 in the solvent of choice, which should be purged with an inert gas. SB 222200 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of SB 222200 in ethanol is approximately 15 mg/ml and approximately 10 mg/ml in DMSO and DMF.

SB 222200 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SB 222200 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. SB 222200 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SB 222200 is a neurokinin-3 (NK₃) receptor antagonist (IC₅₀ = 18.4 nM).¹ It is selective for NK₃ over NK₁ and NK₂ receptors (IC₅₀s = 250 and >100,000 nM, respectively). SB 222200 decreases calcium mobilization induced by neurokinin B (Item No. 24542) with an IC₅₀ value of 265 nM in HEK293 cells expressing the recombinant human receptor. It inhibits contractions induced by senktide (Item No. 16721) in isolated rabbit iris sphincter muscle when used at a concentration of 300 nM. SB 222200 (500 pmol, i.c.v.) decreases mean arterial pressure in spontaneously hypertensive, but not normotensive, rats.² It prevents senktide-induced head shakes and tail whips in mice (ED₅₀ = 5.6 mg/kg).¹

References

1. Sarau, H.M., Griswold, D.E., Bush, B., *et al.* Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist. *J. Pharmacol. Exp. Ther.* **295**(1), 373-381 (2000).
2. Lessard, A., Laurin, M., Yamaguchi, N., *et al.* Central anti-hypertensive effect of tachykinin NK₃ receptor antagonists in rat. *Eur. J. Pharmacol.* **486**(1), 75-83 (2004).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/03/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM